Beschreibung
Fluoxetine may reduce clopidogrel's antiplatelet efficacy by inhibiting CYP2C19-mediated bioactivation while also independently impairing platelet serotonin-mediated aggregation.
Mechanismus
Fluoxetine and norfluoxetine inhibit CYP2C19, reducing clopidogrel activation; paradoxically, fluoxetine's platelet serotonin depletion may partially offset this, but the net antiplatelet effect is uncertain.
Klinische Bedeutung
The clinical outcome impact is not well quantified; caution is warranted in high-risk cardiovascular patients on clopidogrel.
Maßnahmen
Prefer escitalopram or sertraline (weaker CYP2C19 inhibition) when an SSRI is needed alongside clopidogrel.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.